Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
Globe Newswire•04/11/2026•08:00 ET
0
Key Highlights
- ➤STX-1150 single dose provides persistent LDL-C control for at least two years in non-human primates
- ➤STX-1150 is being evaluated in a first-in-human Phase 1 trial
- ➤STX-1200 prototype achieves robust, durable Lp(a) reduction across preclinical models
- ➤Scribe will present two programs at AHA Scientific Sessions November 6-9, 2026
Expert Statements
Benjamin Oakes, Co-founder and CEO of Scribe Therapeutics
“The Entrepreneur's Journey: From Idea to Impact”
Benjamin Oakes, Co-founder and CEO of Scribe Therapeutics
“AI and the Future of Cardiovascular Innovation”
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials
A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe’s gene editing program designed to lower lipoprotein(a)
Get started
Create a free account to read the full story.